Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update

[1]  C. Karam,et al.  Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR , 2021, Neurology and Therapy.

[2]  M. Kosinski,et al.  Responder analysis for neuropathic impairment and quality-of-life assessment in patients with hereditary transthyretin amyloidosis with polyneuropathy in the NEURO-TTR study , 2021, Journal of Neurology.

[3]  C. Karam,et al.  Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis , 2021, BMC Neurology.

[4]  D. Pareyson,et al.  Hereditary transthyretin amyloidosis overview , 2020, Neurological Sciences.

[5]  J. Healey,et al.  What Are the Minimum Clinically Important Differences in SF-36 Scores in Patients with Orthopaedic Oncologic Conditions? , 2020, Clinical orthopaedics and related research.

[6]  F. Salvi,et al.  Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial , 2020, European journal of neurology.

[7]  M. de Carvalho,et al.  Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study , 2020, Orphanet Journal of Rare Diseases.

[8]  P. Hawkins,et al.  Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy , 2020, Journal of Neurology.

[9]  M. Gertz,et al.  Advances in the treatment of hereditary transthyretin amyloidosis: A review , 2019, Brain and behavior.

[10]  M. Kürtüncü,et al.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2019, Turkish Journal Of Neurology.

[11]  M. Fehlings,et al.  Minimum Clinically Important Difference in SF-36 Scores for Use in Degenerative Cervical Myelopathy , 2018, Spine.

[12]  W. Lenderking,et al.  Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers , 2018, Neurology and Therapy.

[13]  D. Adams,et al.  Familial amyloid polyneuropathy , 2017, Current opinion in neurology.

[14]  M. Gertz.  Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. , 2017, The American journal of managed care.

[15]  T. Tripp,et al.  Clinical measures in transthyretin familial amyloid polyneuropathy , 2017, Muscle & nerve.

[16]  Sanjiv J. Shah,et al.  Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). , 2016, Journal of the American College of Cardiology.

[17]  B. Hazenberg,et al.  First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy , 2016, Current opinion in neurology.

[18]  M. Benson,et al.  Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. , 2015, Journal of the American College of Cardiology.

[19]  P. Hawkins,et al.  Quality of life in ATTR amyloidosis , 2015, Orphanet Journal of Rare Diseases.

[20]  O. Karayal,et al.  THAOS: Gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease , 2014, Orphanet Journal of Rare Diseases.

[21]  B. Roitberg,et al.  Usefulness of minimum clinically important difference for assessing patients with subaxial degenerative cervical spine disease: statistical versus substantial clinical benefit , 2013, Acta Neurochirurgica.

[22]  M. Maurer,et al.  THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis , 2013, Current medical research and opinion.

[23]  P. Dyck,et al.  Dissociated sensation in amylidosis. Compound action potential, quantitative histologic and teased-fiber, and electron microscopic studies of sural nerve biopsies. , 1969, Archives of neurology.